Literature DB >> 3151755

Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas' disease).

J A Castro1, E G Diaz de Toranzo.   

Abstract

American trypanosomiasis (Chagas' disease) is an endemic parasitic disease afflicting more than 20 million persons in Latin America. Two drugs are currently being used for treatment of the acute phase of Chagas' disease: 4-[(5-nitrofurfurylidene)amino-3-methylthiomorpholine-1,1-di oxide] (Nifurtimox; Nfx) and (N-benzl-2-nitro-1-imidazole acetamide) (Benznidazole; Bz). Nfx and Bz have serious undesirable effects, which have been reported during their clinical use, including anorexia and weight loss, nausea and vomiting, nervous excitation, insomnia, psyche depressions, convulsions, vertigo, headache, sleepiness, myalgias, arthralgias, loss of balance, disorientation, forgetfulness, paresthesias, adynamia, acoustic phenomena, peripheral neuropathies, gastralgia, mucosal edema, hepatic intolerance, skin manifestations, and intolerance to drinking alcohol. Effects in the central and peripheral nervous system of Nfx were also reproduced in animals. Signs of testicular and ovarian injury were reported for both Nfx and Bz, the effects of Bz being in general less intense than those of Nfx. Both drugs evidenced mutagenicity. In light of the present knowledge about the toxicity of Nfx and Bz, further studies on the mutagenic, teratogenic, carcinogenic, and reproductive effects of both drugs are recommended. Lack of information is particularly serious for Bz. Studies on Nfx and Bz biotransformation, activation to reactive metabolites, and potential mechanisms for their toxic effects were analyzed. Risk-benefit considerations of the use of Nfx and Bz were made and an analysis of the need for research on Chagas' disease chemotherapy was also performed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3151755

Source DB:  PubMed          Journal:  Biomed Environ Sci        ISSN: 0895-3988            Impact factor:   3.118


  22 in total

1.  Buthionine sulfoximine increases the toxicity of nifurtimox and benznidazole to Trypanosoma cruzi.

Authors:  Mario Faundez; Laura Pino; Paula Letelier; Carla Ortiz; Rodrigo López; Claudia Seguel; Jorge Ferreira; Mario Pavani; Antonio Morello; Juan Diego Maya
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  Severe invalidating pain syndrome associated with benznidazole therapy for Chagas' disease.

Authors:  Concepción Moll; Pilar Peris; Asunción Moreno; José Muñoz; Nuria Guañabens
Journal:  Clin Rheumatol       Date:  2007-08-17       Impact factor: 2.980

3.  Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas' disease.

Authors:  R Jeffrey Neitz; Clifford Bryant; Steven Chen; Jiri Gut; Estefania Hugo Caselli; Servando Ponce; Somenath Chowdhury; Haichao Xu; Michelle R Arkin; Jonathan A Ellman; Adam R Renslo
Journal:  Bioorg Med Chem Lett       Date:  2015-06-23       Impact factor: 2.823

4.  Development of resazurin microtiter assay for drug sensibility testing of Trypanosoma cruzi epimastigotes.

Authors:  Miriam Rolón; Celeste Vega; José A Escario; Alicia Gómez-Barrio
Journal:  Parasitol Res       Date:  2006-02-28       Impact factor: 2.289

5.  Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease.

Authors:  Carolina Davies; Rubén Marino Cardozo; Olga Sánchez Negrette; María Celia Mora; Man Chin Chung; Miguel Angel Basombrío
Journal:  Antimicrob Agents Chemother       Date:  2010-06-21       Impact factor: 5.191

6.  New method for quantification of Trypanosoma cruzi in animal's tissue in the chronic phase of experimental Chagas' disease.

Authors:  Viviane Rodrigues Esperandim; Daniele da Silva Ferreira; Miriam Paula Alonso Toldo; Juliana Saraiva; Mariana Bryan Augusto; Sérgio de Albuquerque
Journal:  Parasitol Res       Date:  2010-02-23       Impact factor: 2.289

7.  A new pharmacological screening assay with Trypanosoma cruzi epimastigotes expressing beta-galactosidase.

Authors:  C Vega; M Rolón; A R Martínez-Fernández; J A Escario; A Gómez-Barrio
Journal:  Parasitol Res       Date:  2005-01-29       Impact factor: 2.289

8.  Trypanothione-dependent glyoxalase I in Trypanosoma cruzi.

Authors:  Neil Greig; Susan Wyllie; Tim J Vickers; Alan H Fairlamb
Journal:  Biochem J       Date:  2006-12-01       Impact factor: 3.857

9.  Genotoxicity revaluation of three commercial nitroheterocyclic drugs: nifurtimox, benznidazole, and metronidazole.

Authors:  Annamaria Buschini; Lisa Ferrarini; Susanna Franzoni; Serena Galati; Mirca Lazzaretti; Francesca Mussi; Cristina Northfleet de Albuquerque; Tânia Maria Araújo Domingues Zucchi; Paola Poli
Journal:  J Parasitol Res       Date:  2009-10-21

10.  Evidence for hydroxyl free radical formation during paraquat but not for nifurtimox liver microsomal biotransformation. A dimethyl-sulfoxide scavenging study.

Authors:  G D Castro; A Lopez; J A Castro
Journal:  Arch Toxicol       Date:  1988       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.